339
Haude M, Lee SWL, Worthley SG, Silber S, Verheye S, Rosli MA, Botelho R, Sim KH, Abizaid A, Mehran R, Investigators RT.
The REMEDEE trial: 5-Year results on a novel combined sirolimus-eluting and endothelial progenitor cells capturing stent
Catheter Cardiovasc Interv. 2020;95:1076-1084
privater Sonderdruck
338
Silber S.
ESC-Leitlinie 2019 zum chronischen Koronarsyndrom (CCS, vormals „stabile KHK“) Was ist neu? Was ist besonders wichtig?
Herz. 2019;44:676-683
privater Sonderdruck
337
Silber S.
DMP „Chronische Herzinsuffizienz“ – Ziele und Limitationen
MMW Fortschr Med. 2019;161:40-44
privater Sonderdruck
336
Siontis GC, Branca M, Serruys P, Silber S, Raber L, Pilgrim T, Valgimigli M, Heg D, Windecker S, Hunziker L.
Impact of left ventricular function on clinical outcomes among patients with coronary artery disease
European Journal of Preventive Cardiology. 2019;26:1273-1284
privater Sonderdruck
335
Kelbaek H, Yeh RW, Engstrom T, Neumann FJ, Serruys PW, Windecker S, Belardi J, Qiao S, Xu B, Liu M, Silber S.
Five-year clinical outcomes for the Resolute zotarolimus-eluting stent in total coronary occlusions
EuroIntervention. 2021, 16: 1326 -1332
privater Sonderdruck
334
Garcia-Garcia HM, McFadden EP, von Birgelen C, Rademaker-Havinga T, Spitzer E, Kleiman NS, Cohen DJ, Kennedy KF, Camenzind E, Mauri L, Steg PG, Wijns W, Silber S, van Es GA, Serruys PW, Windecker S, Cutlip D, Vranckx P.
Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention
JACC Cardiovasc Interv. 2019;12:1954-1962
privater Sonderdruck
333
Grammer TB, Dressel A, Gergei I, Kleber ME, Laufs U, Scharnagl H, Nixdorff U, Klotsche J, Pieper L, Pittrow D, Silber S, Wittchen HU, März W.:
Cardiovascular risk algorithms in primary care:
Results from the DETECT study.
Sci Rep. 2019;9:1101
privater Sonderdruck
332
Lindner O, Bauersachs J, Bengel FM, Burchert W, Vom Dahl J, Dorr R, Hacker M, Kelm M, Rassaf T, Rischpler C, Schafer W, Schafers MA, Silber S, Zimmermann R.
Positionspapier Nuklearkardiologie – Update 2018:
Aktueller Stand der klinischen Anwendung
Kardiologe: 2018; 12: 303 - 311
und
Nuklearmedizin. 2018; 57:146-152
privater Sonderdruck
331
Kische H, Hoyer J, Pieper L, Venz J, Klotsche J, Marz W, Koch-Gromus U, Pittrow D, Lehnert H, Silber S, Stalla GK, Zeiher AM, Wittchen HU, Haring R.
Testosterone is not associated with traits of optimism or pessimism: Observational evidence from the prospective DETECT study.
PLoS One. 2018;13:e0207870
privater Sonderdruck
330
Boeckel JN, Palapies L, Klotsche J, Zeller T, von Jeinsen B, Perret MF, Kleinhaus SL, Pieper L, Tzikas S, Leistner D, Bickel C, Stalla GK, Lehner H, Lindahl B, Wittchen HU, Silber S, Baldus S, Maerz W, Dimmeler S, Blankenberg S, Münzel T, Zeiher AM, Keller T:
Adjusted Troponin I for Improved Evaluation of Patients with Chest Pain
Nature - Scientific Reports, 2018, 8:8087
privater Sonderdruck
329
Kische H, Pieper L, Venz J, Klotsche J, Marz W, Koch-Gromus U, Pittrow D, Lehnert H, Silber S, Stalla GK, Zeiher AM, Wittchen HU, Haring R:
Longitudinal change instead of baseline testosterone predicts depressive symptoms
Psychoneuroendocrinology. 2018;89:7-12
privater Sonderdruck
328
Silber S.
Kennen Sie Ihr Herzinfarktrisiko ?
Journal für Kardiologie (Österreich)
(genehmigter Nachdruck der MMW Arbeit)
2018, 25: 135-139
privater Sonderdruck
327
Albus C, Barkhausen J, Fleck E, Haasenritter J, Lindner O, Silber S
für die Leitliniengruppe NVL Chronische KHK
Diagnostik der chronischen koronaren Herzkrankheit
Klinische Leitlinie
Deutsches Ärzteblatt, 2017; 114: 712–719
privater Sonderdruck
Zusatzmaterial
Diskussion und Schlusswort
Deutsches Ärzteblatt, 2018; 115: 131–132
privater Sonderdruck
326
Silber, S.
Verdacht auf stabile KHK:
Wann zum Herzkatheter überweisen ?
MMW - Fortschritte der Medizin, 2017; 159: 46-48
privater Sonderdruck
325
Silber, S.
Thrombozytenhemmung doppelt und für drei zusätzliche Jahre ?
MMW - Fortschritte der Medizin, 2017; 159: 49-52
privater Sonderdruck
324
Yeh RW, Silber S, Chen L, Chen S, Hiremath S, Neumann FJ, Qiao S, Saito S, Xu B, Yang Y, Mauri L.
5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program
JACC Cardiovasc Interv. 2017;10:247-254
privater Sonderdruck
323
Cutlip DE, Garratt KN, Novack V, Barakat M, Meraj P, Maillard L, Erglis A, Jauhar R, Popma JJ, Stoler R, Silber S
9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System
JACC Cardiovasc Interv. 2017;10:160-167
privater Sonderdruck
322
Fajadet J, Neumann FJ, Hildick-Smith D, Petronio S, Zaman A, Spence M, Wohrle J, Elhadad S, Roberts D, Hovasse T, Valdes M, Silber S.
Twelve-Month Results of A Prospective, Multicentre Trial to Assess the Everolimus-Eluting Coronary Stent System (Promus Element): The PLATINUM PLUS All Comers Randomised Trial.
EuroIntervention. 2017;12:1595-1604
privater Sonderdruck
321
Keller T, Boeckel JN, Gross S, Klotsche J, Palapies L, Leistner D, Pieper L, Stalla GK, Lehnert H, Silber S, Pittrow D, Maerz W, Dorr M, Wittchen HU, Baumeister SE, Volker U, Felix SB, Dimmeler S, Zeiher AM.
Improved risk stratification in prevention by use of a panel of selected circulating microRNAs.
Sci Rep. 2017;7:4511
privater Sonderdruck
320
Di Mario C, Serruys PW, Silber S, Lu S, Wang W, Widimsky P, Xu B, Windecker S.
Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Comers Trial and the RESOLUTE Global Clinical Trial Program.
EuroIntervention, 2016;12:1207-1214
privater Sonderdruck
319
Silber S, Witzenbichler B, Vester E.
Optimale orale Thrombozytenaggregationshemmung (TAH) bei Patienten mit und nach akutem Koronarsyndrom (ACS):
Wann beginnen, womit und wie lange?
Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V.,
Update, 3. Version, Herbst 2016
privater Sonderdruck
318
Helms TM, Silber S, Schäfer A, Masuhr F, Palm F, Darius H, Schrör K, Bansch D, Bramlage P, Hankowitz J, Karle CA, Stargardt T, Weil J, Geller JC.
Konsensuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern
Herzschrittmachertherapie & Elektrophysiologie. 2016; 27:295-306
privater Sonderdruck
317
Pilgrim T, Vranckx P, Valgimigli M, Stefanini GG, Piccolo R, Rat J, Rothenbuhler M, Stortecky S, Raber L, Blochlinger S, Hunziker L, Silber S, Juni P, Serruys PW, Windecker S.
Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction.
Am Heart J. 2016;175:56-65
privater Sonderdruck
316
Abdel-Wahab M, Neumann FJ, Serruys PW, Silber S, Leon M, Mauri L, Yeung A, Belardi JA, Widimsky P, Meredith I, Saito S, Richardt G.
Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program
EuroIntervention, 2016, 12:465-472
privater Sonderdruck
315
Piccolo R, Franzone A, Koskinas KC, Raber L, Pilgrim T, Valgimigli M, Stortecky S, Rat-Wirtzler J, Silber S, Serruys PW, Juni P, Heg D, Windecker S.
Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Am J Cardiol. 2016;118:345-352
privater Sonderdruck
314
Styllou P, Silber S.
A case report of the new PolyzeneTM-F COBRA PzFTM Nanocoated Coronary Stent System (NCS): Addressing an unmet clinical need
Cardiovasc Revasc Med, 2016; 17:209-211
privater Sonderdruck
313
Belardi J, Manoharan G, Albertal M, Widimsky P, Neumann FJ, Silber S, Leon MB, Saito S.
The influence of age on clinical outcomes in patients treated with the resolute zotarolimus-eluting stent.
Catheter Cardiovasc Interv. 2016;87:253-261
privater Sonderdruck
312
Koskinas KC, Siontis GC, Piccolo R, Franzone A, Haynes A, Rat-Wirtzler J, Silber S, Serruys PW, Pilgrim T, Raber L, Heg D, Juni P, Windecker S.
Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients
Circ Cardiovasc Interv. 2016;9:e003255
privater Sonderdruck
311
310
Silber S., Witzenbichler B, Vester E.
Optimale orale Thrombozytenaggregationshemmung (TAH) bei Patienten mit und nach akutem Koronarsyndrom (ACS):
Wann beginnen, womit und wie lange?
Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V.,
Update 2015
privater Sonderdruck
309
Vranckx P, Kalesan B, Stefanini GG, Farooq V, Onuma Y, Silber S, de Vries T, Juni P, Serruys PW, Windecker S.
Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention.
EuroIntervention, 2015;11:171-179
privater Sonderdruck
308
Kelbaek H, Holmvang L, Richardt G, Eberli FR, Stella P, Buszman PE, Neumann FJ, Serruys PW, Windecker S, Widimsky P, Belardi JA, Silber S.
Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions.
EuroIntervention. 2015;11:650-657
privater Sonderdruck
307
Chevalier B, Wijns W, Silber S, Garcia E, Serra A, Paunovic D, Serruys P, investigators N.
Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial.
EuroIntervention. 2015;11:549-554
privater Sonderdruck
306
Dudek D, Dziewierz A, Brener SJ, Abizaid A, Merkely B, Costa RA, Bar E, Rakowski T, Kornowski R, Dressler O, Abizaid A, Silber S, Stone GW.
Mesh-covered embolic protection stent implantation in ST-segment-elevation myocardial infarction: final 1-year clinical and angiographic results from the MGUARD for acute ST elevation reperfusion trial.
Circ Cardiovasc Interv. 2015;8:e001484
privater Sonderdruck
305
Diletti R, Garcia-Garcia HM, Bourantas C, Van Mieghem NM, van Geuns RJ, Muramatsu T, Zhang YJ, Mauri L, Belardi J, Silber S, Widimsky P, Leon M, Windecker S, Meredith I, Neumann FJ, Yeung AC, Saito S, Liu M, van Leeuwen F, Serruys PW.
Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program.
Catheter Cardiovasc Interv. 2015;85:952-958
privater Sonderdruck
304
Piccolo R, Pilgrim T, Heg D, Franzone A, Rat-Wirtzler J, Raber L, Silber S, Serruys PW, Juni P, Windecker S.
Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients.
JACC Cardiovasc Interv. 2015;8:1657-1666
privater Sonderdruck
303
Costa RA, Abizaid A, Lotan C, Dudek D, Silber S, Dizon JM, Maehara A, Dressler O, Brener SJ, Stone GW.
Impact of thrombus burden on outcomes after standard versus mesh-covered stents in acute myocardial infarction (from the MGuard for acute ST elevation reperfusion trial).
Am J Cardiol. 2015;115:161-166
privater Sonderdruck
302
Silber S.
Stentvergleich bei KHK: Vollständig absorbierbare Stents bringen keinen gesicherten Vorteil
Dtsch Med Wochenschr. 2015;140:386
privater Sonderdruck
301
Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, Negoita M, Buszman PE, Windecker S.
Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial
Circ Cardiovasc Interv. 2015;8:e002230
privater Sonderdruck
300
Bourantas CV, Zhang YJ, Garg S, Iqbal J, Valgimigli M, Windecker S, Mohr FW, Silber S, Vries T, Onuma Y, Garcia-Garcia HM, Morel MA, Serruys PW.
Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials.
Heart, 2014;100:1158-1164
privater Sonderdruck
299
Vester EG, Bocksch W, Dörr R, Grebe O, Hoffmann S, Leitsch T, Silber S.
Orale Antikoagulation bei interventionellen Eingriffen in der Kardiologie,
Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V.,
Sommer 2014
privater Sonderdruck
298
Kotzerke J, Silber S.
Endovascular Brachytherapy to Prevent Restenosis After Percutaneous Coronary Intervention
Buchkapitel in: Therapeutic Nuclear Medicine, Editor: Richard P. Baum,
Springer-Verlag Berlin Heidelberg 2014, ISSN 0942-5373
privater Sonderdruck
297
Witt S, Leidl R, Becker C, Holle R, Block M, Brachmann J, Silber S, Stollenwerk B.
The effectiveness of the cardiovascular disease prevention programme 'KardioPro' initiated by a German sickness fund: a time-to-event analysis of routine data.
PLoS One. 2014;9:e114720
privater Sonderdruck
296
Leistner DM, Klotsche J, Palm S, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM for the DETECT study group.
Prognostic value of reported chest pain for cardiovascular risk stratification in primary care.
European Journal of Preventive Cardiology. 2014;21:727-738
privater Sonderdruck
295
Loh JP, Stella PR, Sangiorgi G, Silber S, Stahnke S, von Strandmann RP, Torguson R, Waksman R.
Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.
Cardiovascular Revascularization Medicine, 2014;15:23-28
privater Sonderdruck
294
Schäfer A, Arntz HR, Boudriot E, Garlichs C, Hoffmann S, Ince H, Klingenheben T, Weil J, Zugck C, Helms TM, Silber S.
Differenzierte antithrombozytäre Therapie bei akutem Koronarsyndrom
Dtsch Med Wochenschr, 1390: 152–158 (2014)
privater Sonderdruck
293
Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, European Society of Cardiology Committee for Practice G, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Committee ECG, Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner HO, Wassmann S, Wendler O, Zamorano JL, Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S, European Association of Percutaneous Cardiovascular I.
2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).
Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Eur J Cardiothorac Surg. 2014;46:517-592
privater Sonderdruck
292
Aljutaili M, Becker C, Witt S, Holle R, Leidl R, Block M, Brachmann J, Silber S, Bestehorn K, Stollenwerk B.
Should health insurers target prevention of cardiovascular disease? A cost-effectiveness analysis of an individualised programme in Germany based on routine data.
BMC Health Serv Res. 2014;14:263
privater Sonderdruck
291
Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S.
4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
J Am Coll Cardiol. 2014;63:1617-1625
privater Sonderdruck
290
Stefanini GG, Taniwaki M, Kalesan B, Raber L, Stortecky S, Pilgrim T, Onuma Y, Silber S, Serruys PW, Meier B, Juni P, Windecker S.
The impact of renal impairment on long-term safety and effectiveness of drug-eluting stents.
PLoS One. 2014;9:e106450
privater Sonderdruck
289
Ferenc M, Kornowski R, Belardi J, Serruys P, Silber S, Widimsky P, Windecker S, Neumann FJ.
Three-year outcomes of percutaneous coronary intervention with next-generation zotarolimus-eluting stents for de novo coronary bifurcation lesions.
J Invasive Cardiol. 2014;26:630-638
privater Sonderdruck
288
Caputo R, Leon M, Serruys P, Neumann FJ, Yeung A, Windecker S, Belardi JA, Silber S, Meredith I, Widimsky P, Saito S, Mauri L.
Performance of the resolute zotarolimus-eluting stent in small vessels.
Catheter Cardiovasc Interv. 2014;84:17-23
privater Sonderdruck
287
Dudek D, Brener SJ, Rakowski T, Dziewierz A, Abizaid A, Silber S, Yaacoby E, Dizon JM, Costa RA, Maehara A, Dressler O, Stone GW.
Efficacy of an Embolic Protection Stent as a Function of Delay to Reperfusion in ST-Segment Elevation Myocardial Infarction (from the MASTER Trial).
Am J Cardiol. 2014;114:1485-1489
privater Sonderdruck
286
Silber S, Kirtane AJ, Belardi JA, Liu M, Brar S, Rothman M, Windecker S.
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Eur Heart J. 2014;35:1949-1956
privater Sonderdruck
285
284
Widimsky P, Motovska Z, Belardi J, Serruys P, Silber S, Windecker S, Neumann FJ.
Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program.
Int J Cardiol. 2013;168:3522-3526
privater Sonderdruck
283
Willich SN, Müller-Riemenschneider F, McBride D, Silber S, Kuck KH, Nienaber CA, Schneider S, Senges J, Brüggenjürgen B.
Health economic evaluation of the use of drug-eluting stents : First results from the Drug-Eluting Stent Registry (DES.de).
Herz, 2013; 38:57-64
privater Sonderdruck
282
Vranckx P, McFadden E, Cutlip DE, Mehran R, Swart M, Kint PP, Zijlstra F, Silber S, Windecker S, Serruys PW.
Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: methodology and external validation.
Contemporary Clinical Trials. 2013;34:53-59
privater Sonderdruck
281
Silber S, Serruys PW, Leon MB, Meredith IT, Windecker S, Neumann FJ, Belardi J, Widimsky P, Massaro J, Novack V, Yeung AC, Saito S, Mauri L.
Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
JACC Cardiovasc Interv. 2013;6:366-377
privater Sonderdruck
280
Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P.
Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
JACC Cardiovasc Interv. 2013;6:905-913
privater Sonderdruck
279
Leistner DM, Klotsche J, Pieper L, Palm S, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study.
Clin Res Cardiol. 2013;102:259-268
privater Sonderdruck
278
Haude M, Lee SW, Worthley SG, Silber S, Verheye S, Erbs S, Rosli MA, Botelho R, Meredith I, Sim KH, Stella PR, Tan HC, Whitbourn R, Thambar S, Abizaid A, Koh TH, Den Heijer P, Parise H, Cristea E, Maehara A, Mehran R.
The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
JACC Cardiovasc Interv. 2013;6:334-343
privater Sonderdruck
277
Farooq V, Vranckx P, Mauri L, Cutlip DE, Belardi J, Silber S, Widimsky P, Leon M, Windecker S, Meredith I, Negoita M, van Leeuwen F, Neumann FJ, Yeung AC, Garcia-Garcia HM, Serruys PW.
Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program.
Heart. 2013;99:626-633
privater Sonderdruck
276
Costa JR, Jr., Abizaid A, Dudek D, Silber S, Leon MB, Stone GW.
Rationale and design of the MGuard for acute ST elevation reperfusion MASTER trial.
Catheter Cardiovasc Interv. 2013;82:184-190
privater Sonderdruck
275
Bramlage P, Cuneo A, Zeymer U, Hochadel M, Richardt G, Silber S, Senges J, Nienaber CA, Tebbe U, Kuck KH.
Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents.
Clin Res Cardiol. 2013;102:289-297
privater Sonderdruck
274
Diletti R, Garcia-Garcia HM, Bourantas CV, van Geuns RJ, Van Mieghem NM, Vranckx P, Zhang YJ, Farooq V, Iqbal J, Wykrzykowska JJ, de Vries T, Swart M, Teunissen Y, Negoita M, van Leeuwen F, Silber S, Windecker S, Serruys PW
Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial.
Heart, 2013;99:1267-1274
privater Sonderdruck
273
Silber S, Basler M, Gerhard N:
Possibilities and obstacles of the German Reimbursement System (G-DRG) for the implementation of guideline-recommended adjunctive technical devices for percutaneous coronary interventions
Confluence, Issue 6, 12 - 15, (2012)
privater Sonderdruck
272
Silber S.
The RESOLUTE clinical programme: one month DAPT data presented at TCT
Confluence, Issue 6, 31 - 33, (2012)
privater Sonderdruck
271
Labeit AM, Klotsche J, Pieper L, Pittrow D, Einsle F, Stalla GK, Lehnert H, Silber S, Zeiher AM, Marz W, Wehling M, Wittchen HU.
Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients.
PLoS One. 2012;7:e52229
privater Sonderdruck
270
Vranckx P, Farooq V, Garg S, Van Es GA, Silber S, Windecker S, Stone GW, Serruys PW.
Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting.
Heart. 2012;98:1424-1430
privater Sonderdruck
269
Stone GW, Abizaid A, Silber S, Dizon JM, Merkely B, Costa RA, Kornowski R, Abizaid A, Wojdyla R, Maehara A, Dressler O, Brener SJ, Bar E, Dudek D:
Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial.
J Am Coll Cardiol, 60:1975–1984 (2012)
privater Sonderdruck
268
Stefanini GG, Kalesan B, Pilgrim T, Raber L, Onuma Y, Silber S, Serruys PW, Meier B, Juni P, Windecker S.
Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents.
JACC Cardiovasc Interv; 5:301-310 (2012)
privater Sonderdruck
267
Van de Werf F, Ardissino D, Bueno H, Collet JP, Gershlick A, Kolh P, Kristensen SD, Silber S, Verheugt F, Wojakowski W.
Acute coronary syndromes: Considerations for improved acceptance and implementation of management guidelines.
Expert Rev Cardiovasc Ther; 10:489-503 (2012)
privater Sonderdruck
266
Neumann FJ, Cremer J, Falk V, Reifart N, Silber S, Thielmann M.
Kommentar zu den gemeinsamen „Guidelines on Myocardial Revascularization“ der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS)
Der Kardiologe; 6: 94 – 104 (2012)
privater Sonderdruck
265
Abdel-Wahab M, Nienaber CA, Mostafa AE, Ferenc M, Silber S, Sabin G, Tebbe U, Akin I, Hochadel M, Senges J, Kuck KH, Richardt G.
Treatment of coronary bifurcation lesions with drug-eluting stents: Insights from the first phase of the prospective multicenter german drug-eluting stent registry.
J Interv Cardiol. 2012;25:344-352
privater Sonderdruck
264
Beijk MA, Damman P, Klomp M, Woudstra P, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter AR.
Twelve-month clinical outcomes after coronary stenting with the genous bio-engineered R stent in patients with a bifurcation lesion: From the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) registry.
Coronary Artery Disease; 23:201-207 (2012)
privater Sonderdruck
263
Damman P, Klomp M, Silber S, Beijk MA, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ.
Duration of dual antiplatelet therapy and outcomes after coronary stenting with the genous bio-engineered R stent in patients from the e-HEALING registry.
Catheter Cardiovasc Interv; 79:243-252 (2012)
privater Sonderdruck
262
Klomp M, Damman P, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ.
Applying the national institute for clinical excellence criteria to patients treated with the genous bio-engineered R stent: A sub-study of the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry.
Heart Vessels; 27:360-369 (2012)
privater Sonderdruck
261
Leistner DM, Klotsche J, Palm S, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Resting heart rate as a tool for risk stratification in primary care: Does it provide incremental prognostic information?
European Journal of Preventive Cardiology; 19:275-284 (2012)
privater Sonderdruck
260
Leistner DM, Klotsche J, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention.
Clin Chem; 58:200-208 (2012)
privater Sonderdruck
259
Klomp M, Damman P, Beijk MA, Tan KH, Balian V, de Luca G, Tijssen JG, Silber S, de Winter RJ.
Differences in cardiovascular risk factors and clinical outcomes between western european and southeast asian patients treated with the genous bio-engineered R stent: An e-HEALING worldwide registry substudy.
Coronary Artery Disease; 23:271-277 (2012)
privater Sonderdruck
258
Silber S, Tan HC, Iniguez A, Scacciatella P, Smith D, Kutryk M, Brugaletta S
Relative clinical contraindications to the use of drug-eluting stents: what are the alternatives?
Cardiology International, 45 - 48 (2012)
privater Sonderdruck
257
Schneider HJ, Klotsche J, Friedrich N, Schipf S, Volzke H, Silber S, Marz W, Nauck M, Pittrow D, Wehling M, Sievers C, Lehnert H, Stalla GK, Wittchen HU, Wallaschofski H.
Risk factors associated with the metabolic syndrome in abdominal obesity.
Clin Obes. 2012;2:142-149
privater Sonderdruck
256
Silber S, Helms T, Berger H-J, Braun P, Hoffmann S, Schäfer A, Vester E.
Optimale Thrombozytenaggregationshemmung bei Patienten mit akutem Koronarsyndrom (ACS).
Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V.,
1. Version, Frühjahr 2012
privater Sonderdruck
255
Alfons Schuhbeck im Gespräch mit dem Kardiologen Prof. Dr. med. Sigmund Silber
Die richtige Ernährung für Herz und Kreislauf
Buchkapitel in: A. Schuhbeck: Die Heilkraft von Omega-3, Seiten 24 - 27
Verlag Zabert Sandmann GmbH, München, 1. Auflage 2011, ISBN 978-3-89883-273-1
254
Nationale Versorgungsleitlinien der Bundesärztekammer, Kassenärztlichen Bundesvereinigung und der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften zur chronischen koronaren Herzkrankheit
2011
www.versorgungsleitlinien.de
253
Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK
Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: Insights from the EURO HEART survey PCI registry.
Catheter Cardiovasc Interv; 78:702-709 (2011)
privater Sonderdruck
252
Bauer T, Nienaber CA, Akin I, Kuck KH, Hochadel M, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Zahn R.
Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: Results from the German DES.DE-Registry.
Clin Res Cardiol; 100:701-709 (2011)
privater Sonderdruck
251
Damman P, Iniguez A, Klomp M, Beijk M, Woudstra P, Silber S, Ribeiro EE, Suryapranata H, Sim KH, Tijssen JG, de Winter RJ.
Coronary stenting with the genous bio-engineered R stent in elderly patients.
Circ J; 75:2590-2597 (2011)
privater Sonderdruck
250
Damman P, Klomp M, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ.
Twelve-month outcomes after coronary stenting with the genous bio-engineered R stent in diabetic patients from the e-HEALING registry.
J Interv Cardiol; 24:285-294 (2011)
privater Sonderdruck
249
De Mulder M, Gitt A, van Domburg R, Hochadel M, Seabra-Gomes R, Serruys PW, Silber S, Weidinger F, Wijns W, Zeymer U, Hamm C, Boersma E.
Euroheart score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary intervention.
Eur Heart J; 32:1398-1408 (2011)
privater Sonderdruck
248
den Dekker WK, Houtgraaf JH, Onuma Y, Benit E, de Winter RJ, Wijns W, Grisold M, Verheye S, Silber S, Teiger E, Rowland SM, Ligtenberg E, Hill J, Wiemer M, den Heijer P, Rensing BJ, Channon KM, Serruys PW, Duckers HJ.
Final results of the HEALING-IIb trial to evaluate a bio-engineered cd34 antibody coated stent (Genous stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients.
Atherosclerosis; 219:245-252 (2011)
privater Sonderdruck
247
Garg S, Serruys PW, Silber S, Wykrzykowska J, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Van Remortel E, Ronden J, Windecker S.
The prognostic utility of the syntax score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial.
JACC Cardiovasc Interv; 4:432-441 (2011)
privater Sonderdruck
246
Gomez-Lara J, Heo JH, Brugaletta S, Garg S, Garcia-Garcia HM, van Geuns RJ, Silber S, Windecker S, Serruys PW.
Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents.
Am Heart J; 162:1069-1079 e1062 (2011)
privater Sonderdruck
245
Gutierrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbaek H, Saunamaki K, Escaned J, Gonzalo N, di Mario C, Borgia F, Nuesch E, Garcia-Garcia HM, Silber S, Windecker S, Serruys PW.
Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. A fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: An optical coherence tomography substudy from the resolute all comers trial.
Eur Heart J; 32:2454-2463 (2011)
privater Sonderdruck
244
Schneider HJ, Klotsche J, Silber S, Stalla GK, Wittchen HU.
Measuring abdominal obesity: Effects of height on distribution of cardiometabolic risk factors risk using waist circumference and waist-to-height ratio.
Diabetes Care; 34:e7 (2011)
privater Sonderdruck
243
Silber S, Damman P, Klomp M, Beijk MA, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Hian Sim K, Tijssen JG, de Winter RJ.
Clinical results after coronary stenting with the genous bio-engineered R stent: 12-month outcomes of the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry.
EuroIntervention; 6:819-825 (2011)
privater Sonderdruck
242
Silber S, Gutierrez-Chico JL, Behrens S, Witzenbichler B, Wiemer M, Hoffmann S, Slagboom T, Harald D, Suryapranata H, Nienaber C, Chevalier B, Serruys PW.
Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: The EUROSTAR-II randomised clinical trial.
EuroIntervention; 7:64-73 (2011)
privater Sonderdruck
241
Silber S, Helms TM, Garlichs C, Arntz HR, Weil J, Ince H, Klingenheben T, Hoffmann S, Boudriot E, Steiger H, Zugck C.
Prasugrel in der Akut- und Nachbehandlung des akuten Koronarsyndroms: Wie ist der aktuelle Stand?
Dtsch Med Wochenschr; 136:782-785 (2011)
privater Sonderdruck
240
Silber S, Windecker S, Vranckx P, Serruys PW.
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the resolute all comers trial
Lancet; 377:1241-1247 (2011)
privater Sonderdruck
239
Stefanini GG, Serruys PW, Silber S, Khattab AA, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli AL, Gobbens P, Windecker S.
The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention).
J Am Coll Cardiol; 57:2221-2232 (2011)
privater Sonderdruck
238
Stella PR, Belkacemi A, Waksman R, Stahnke S, Torguson R, von Strandmann RP, Agostoni P, Sangiorgi G, Silber S.
The VALENTINES trial: Results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation dior paclitaxel drug-eluting balloon for in-stent restenosis treatment.
EuroIntervention; 7:705-710 (2011)
privater Sonderdruck
237
Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK.
Predictors of hospital mortality in the elderly undergoing percutaneous coronary intervention for acute coronary syndromes and stable angina.
Int J Cardiol; 151:164-169 (2011)
privater Sonderdruck
236
Silber S.
Immediate and Long-Term Therapy of Patients with Acute Coronary Syndromes with Thienopyridines. Current Status According to the Latest European Society of Cardiology (ESC) Guidelines
RMMJ; 2: e0056 (2011)
privater Sonderdruck
235
Silber S,Van de Werf F. and Members of the Task Force
ESC/DGK Pocket-Leitlinie:
Akutes Koronarsyndrom mit persistierender ST- Streckenhebung (STEMI)
Der Kardiologe; 4:93-106 (2010)
privater Sonderdruck
234
Silber S, Borggrefe M, Hasenfuß G, Falk V, Kastrati A, Weis M, Hamm CW.
Kommentare zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie von Patienten mit ST-Streckenhebungsinfarkt (STEMI)
Der Kardiologe; 4:84-92 (2010)
privater Sonderdruck
233
Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK.
Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: Impact of clinical status and procedural characteristics.
Clin Res Cardiol; 99:375-383 (2010)
privater Sonderdruck
232
Mahabadi AA, Achenbach S, Burgstahler C, Dill T, Fischbach R, Knez A, Moshage W, Richartz BM, Ropers D, Schröder S, Silber S, Möhlenkamp S.
Safety, efficacy, and indications of beta-adrenergic receptor blockade to reduce heart rate prior to coronary ct angiography.
Radiology; 257:614-623 (2010)
privater Sonderdruck
231
Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, John U, Dorr M, Felix S, Lehnert H, Pittrow D, Silber S, Volzke H, Stalla GK, Wallaschofski H, Wittchen HU.
The predictive value of different measures of obesity for incident cardiovascular events and mortality.
J Clin Endocrinol Metab; 95:1777-1785 (2010)
privater Sonderdruck
230
Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S.
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
N Engl J Med; 363:136-146 (2010)
privater Sonderdruck Originalarbeit
privater Sonderdruck Appendix
229
Silber S.
Evidenzbasiertes Vorgehen beim ST-Strecken- Hebungsinfarkt (STEMI): Neueste Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) 2010
Herz; 35:558-564 (2010)
privater Sonderdruck
228
Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW.
Myocardial infarction adjudication in contemporary all-comer stent trials: Balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies.
EuroIntervention; 5:871-874 (2010)
privater Sonderdruck
227
Hoffmeister HH, Bode C, Darius H, Huber K, Rybak K, Silber S.
Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen
Positionspapier der Deutschen Gesellschaft für Kardiologie (DGK)
Der Kardiologe; 4: 365-374 (2010)
privater Sonderdruck
226
Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D.
Guidelines on Myocardial Revascularization of the European Society of Cardiology (ESC)
Eur Heart J; 31:2501-2555 (2010)
privater Sonderdruck
Eur J Cardiothorac Surg. 2010;38 Suppl:S1-S52
privater Sonderdruck